Presentation on theme: "Affordable Resistance Testing for Africa (ART-A)"— Presentation transcript:
1Affordable Resistance Testing for Africa (ART-A) Michelle BronzeHIV Drug Resistance LaboratoryUniversity of the WitwatersrandNational Health Laboratory ServiceJohannesburg, South Africa
2IntroductionNational ARV programs expand to achieve the UN General Assembly health-related Millennium Development Goals by 2015, which include universal access to HAART, there is an urgent need to expand the technology, laboratory capacity, accessibility and affordability to perform HIVDR testing in resource limited settings.ARV roll-out program initiated in April 2004 and has expanded dramatically, with the latest statistics showing that >2.1 million South Africans are accessing the national roll-out programme.NHLS recognized the need to develop an affordable resistance testing platform, and established the HIV Genotyping Laboratory in 2005 in anticipation of future needs.The Affordable Resistance Test for Africa (ART-A) project was founded to address the need to develop an affordable resistance test.
3In this project, private, academic and civil society stakeholders joined forces to develop an affordable, comprehensive HIV drug resistance protocol which could be universally applied to individual patients by a network of clinics, hospitals and laboratories in Africa. The public-private consortium launched the ART-A project on the 1st of January 2008.
4IntroductionHIV-1 RNA viral load (VL) is the preferred tool to identify virological failure (VF) during antiretroviral therapy (ART).The effectiveness and sustainability of ART is threatened by the emergence of HIV-1 drug resistance (HIVDR).Timely detection of VF can reduce the complexity of HIVDR mutation patterns.The work conducted assessed:a novel affordable two-step approach to identify Virological Failure and detect key HIVDR mutations in order to improve quality of HIV care in resource-limited settings.Moreover, to ensure results could be reproduced in different centre’s, field evaluations were conducted in Uganda where subtype A and D are prevalent, and South Africa & Zimbabwe (high subtype C prevalence) by the ARTA team
5IntroductionSouth Africa is better equipped to manage the local epidemic having significantly more laboratory capacity for toxicity tests, CD4 and viral load assays than many other resource-limited countries.This country has a three-tier laboratory system:regional tertiary reference laboratories (21% of laboratories): VL’s , CD4’s, HIVDR (handle large volumes of work, and for the most part possess appropriate technical resources, including electricity, freezer capacity, dedicated laboratory space, skilled personnel, training programs, reliable internet connections and appropriate quality control systemssecondary or district facilities (10%): medium volume laboratories that also perform CD4 and viral load assays but with a reduced repertoire of tests, and do not have specialized facilitiesprimary health care laboratories (69%): technically non-demanding assays, which typically include rapid and point-of-care testsThe high burden of disease and ever-increasing testing volumes is placing an enormous workload on the current public sector laboratory networks and innovative diagnostic solutions are needed for the future as HAART coverage expands.
6The following approach is how this algorithm would be applied in a clinical setting:
7Virological Failure Assay (ARTA-VFA) A simplified and affordable approach using a qualitative viral load assay with a pre-determined cut-off that gives a threshold above which VF could be confirmed and below, treatment success was likely.RNA extraction from plasma/DBS cDNA synthesis real-time PCR amplification of a short sequence of the HIV-1 LTR region.Its applicability using either plasma or DBS was confirmed, with virological failure being qualitatively classified as a viral load >1000 RNA copies/ml in plasma samples, and >5000 RNA copies/ml in DBS samples.The ARTA-VFA identified all major HIV-1 group M subtypes with equal specificity.Accurate virological failure determination for therapy-switching in approximately 93% of clinical cases tested.
8ARTA-VFAPerformance of VFA – linearity and classifications around 5000 and 1000 copies/ml cut-off’sBronze et al. (2013) Journal of Virological Methods
9Performance of VFA (South Africa) – Performance characteristics around the 5000 and 1000 copies/ml cut-off’sComparison5000 copies/ml cut-off1000 copies/ml cut-offSensitivity (%)Specificity (%)PPV (%)NPV (%)Plasma VFA vs. EasyQ v1.295939296909886DBS VFA vs. EasyQ v1.2911007072DBS VFA vs. Plasma VFA76Sensitivity: True virological failure/ (True virological failure + False non-virological failure)Specificity: True non-virological failure/ (True non-virological failure + False virological failure)Positive predictive value: True virological failure/ (True virological failure + False virological failure)Negative predictive value: True non-virological failure/ (True non-virological failure + False non-virological failure)Bronze et al. (2013) Journal of Virological Methods
10Performance of VFA on DBS (South Africa) Bronze et al. (2013) Journal of Virological Methods
11Performance of VFA across three study sites in Uganda 5000 cp/ml cut-offSensitivity (%)Specificity (%)PPV (%)NPV (%)Kampala7892Fort Portal80947496Mbale9586Combined8387Balinda et al. (2012) ASLMPerformance of VFA at Newlands Clinic, ZimbabweComparison5000 copies/ml cut-off1000 copies/ml cut-offSensitivity (%)Specificity (%)PPV (%)NPV (%)Plasma VFA vs. TaqMan8597959388989676DBS VFA vs. TaqMan33995310078Ondoa et al. (Unpublished)
12Overall Performance of VFA on DBS in RSA, Uganda and Zimbabwe Comparison5000 copies/ml cut-offSensitivity (%)Specificity (%)PPV (%)NPV (%)RSA919596Uganda83938792Zimbabwe33999776Bronze et al. (2013) Journal of Virological MethodsBalinda et al. (2012) ASLMOndoa et al. (Unpublished)Ondoa et al. (Unpublished)
13Short RT HIV Drug Resistance Assay (ARTA-HIVDRultralight) The ARTA-HIVDRultralight assay targets amino acids 41 – 238 of RT (harboring all major RT inhibitor resistance mutation positions, thus providing all relevant susceptibility data for first-line regimen failures)The aimed specifications for this assay:to be practical and affordableflexible with respect to equipment choices (open platform)include the option of DBS or plasmaamplify and sequence a smaller amplicon (RT)
15Performance of ARTA-HIVDRultralight Aitken et al. (2013) Journal of Clinical Microbiology
16ARTA-HIVDRultralight amplification and sequencing rates (South Africa) Aitken et al. (2013) Journal of Clinical MicrobiologyARTA-HIVDRultralight amplification and sequencing rates (South Africa)Bronze et al. (2013) Journal of Virological MethodsSample Size (n)Viral Load (copies/ml)Amplification Success Rate (%)Sequencing Success Rate (%)41>500098 (39/40)85 (33/39)25<5000*44 (11/25)55 (6/11)* The <5000 copies/ml DBS group will be further assessed to assess success rates of assay between the 1000 and 5000 copies/ml range
17Cost of compared HIV-1 viral load and HIV-1 drug resistance genotyping assays (South Africa) Bronze et al. (2013) Journal of Virological Methods
18ConclusionPlasma and DBS sampling extends the access of testing to more remote settings.These assays were designed to either be used as a testing strategy of initially assessing virological failure, and once confirmed performing an HIVDR assay, or alternatively to be used separately as stand-alone, or within different laboratory tiers.Since large scale commercial assays are commonly used in reference laboratory service areas with a large burden of HIV-1, and primary health care centres ideally use rapid or point-of-care assays, the ARTA-VFA could potentially be used in the middle laboratory tier.This would involve screening patients for virological failure with a qualitative outcome (a >1000 RNA copies/ml cut-off for plasma samples, and a >5000 RNA copies/ml cut-off for DBS), followed by referral to a Tier 1 laboratory with the available infrastructure for HIVDR testing using the ARTA-HIVDRultralight if indicated.
19Some lessons learntThis study highlights the importance of validating assays where they are to be used.Costing in one country is not equivalent to all countriesAssays originally designed to be used on plasma require further “tweaking” to increase assay sensitivity for use on DBS